Today, we are excited to announce the winners of our 2nd Annual BioBuzz Awards. The BioBuzz Awards are a celebration of the exciting and groundbreaking work being done by the BioHealth Capital Region (BHCR) life science community and the individuals that make innovation happen across Maryland, Virginia, and Washington, D.C.
United Therapeutics (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2022. This award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list was announced on December 2, 2021, available on Newsweek’s website, recognizes the top 500 most responsible companies in the United States, spanning 14 industries.
We’re excited to announce this year’s finalists for the second annual 2021 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.
United Therapeutics Corporation (Nasdaq: UTHR) today announced it is joining forces with former NFL player Devon Still and his daughter Leah, a survivor of high-risk neuroblastoma, to launch the educational initiative “Braving NeuroBLASToma” shining a light on the rare cancer affecting immature nerve cells called neuroblasts.iv Neuroblastoma often develops in infants and children under the age of five, but the average age of diagnosis is between one and two years old.
United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review the New Drug Application (NDA) for Tyvaso DPI™ (inhaled treprostinil) for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics expects the agency’s review to be complete in October 2021. FDA also indicated that they have not identified any potential review issues at this time.
United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 19, 2021 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced the submission of a [….]
United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the innovative Remunity ® Pump for Remodulin ® for patients with pulmonary arterial hypertension (PAH). “We are excited to bring to market the first subcutaneous pump designed specifically for PAH patients,” said Beth Rhodes, Vice President, Global Supply Chain Alliance Management…
The combination of a booming biotech market with an additional surge of hiring by vaccine and diagnostic companies in Maryland has resulted in record-low unemployment and competition for talent at an all-time high.
Former MedImmune Employees Leading In the BioHealth Capital Region and Beyond In a recent conversation someone shared the quote “You can’t throw a stone in the BioHealth Capital Region and [….]
